["Fast" and "slow" components of psychotropic activity of the drugs with nootropic effects].
A clinical-pharmacological study was carried out to evaluate correlation of "fast" (nonspecific) and "slow" (specific) components of the action of the drugs with nootropic properties (piracetam, mexidol, tanacan) and to estimate their contribution to achieving therapeutic efficacy. The study was performed during 28 days using standard quantitative assay techniques in 79 patients with "Organic emotional-liable (asthenic) disorders" (F06.6, ICD-10). It was found that "fast" component of the psychotropic action of the drugs tested was presented by stimulating and anxiolytic effects, while a "slow" one--by specific nootropic activity. All these effects were fully independent with no correlation found, and this could, probably, be attributed to different mechanisms of their realization. It is shown that nootropic activity of piracetam was most significant in its therapeutic effect; and anxiolytic effect was most important for mexidol action. Meanwhile, stimulating and anxiolytic activities as well as positive influence on long-term memory were main components of tanacan effect. The results obtained show an important role of both specific and nonspecific ("fast") effects in realization of therapeutic action of the drugs with nootropic effects in patients with cognitive-mnestic and neurosis-like disorders.
Neznamov
G G
GG
Siuniakov
S A
SA
Davydova
I A
IA
Teleshova
E S
ES
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005419:Flavonoids / Q000494:pharmacology* / Q000627:therapeutic use; D020441:Ginkgo biloba; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D018697:Nootropic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D010847:Picolines / Q000494:pharmacology* / Q000627:therapeutic use; D010889:Piracetam / Q000494:pharmacology* / Q000627:therapeutic use; D010936:Plant Extracts; D011619:Psychotropic Drugs / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D000096983:Ginkgo Extract
D005419:Flavonoids; D018697:Nootropic Agents; D010847:Picolines; D010889:Piracetam; D010936:Plant Extracts; D011619:Psychotropic Drugs; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract; C070020:emoxypine succinate